Efficacy and toxicity of vemurafenib and cobimetinib in relation to plasma concentrations, after administration via feeding tube in patients with BRAF-mutated thyroid cancer: a case series and review of literature

INTRODUCTION: The combination of vemurafenib, a proto-oncogene B-Raf inhibitor (BRAFi) and cobimetinib, an inhibitor of mitogen-activated protein kinase kinase (MEKi) has shown to improve survival in patients with BRAF V600-mutated melanoma. BRAF mutations are also frequently detected driver mutatio...

Descripción completa

Detalles Bibliográficos
Autores principales: van Berge Henegouwen, J. M., van der Wijngaart, H., Zeverijn, L. J., Hoes, L. R., Meertens, M., Huitema, A. D. R., Devriese, L. A., Labots, M., Verheul, H. M. W., Voest, E. E., Gelderblom, H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9300506/
https://www.ncbi.nlm.nih.gov/pubmed/35598186
http://dx.doi.org/10.1007/s00280-022-04437-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9300506/
https://www.ncbi.nlm.nih.gov/pubmed/35598186
http://dx.doi.org/10.1007/s00280-022-04437-z

Ejemplares similares